by qfrsolutions | Aug 11, 2016 | News
Source: Reuters U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc (VRX.N) over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales, the Wall Street Journal reported...
by qfrsolutions | Aug 1, 2016 | News
Source: Real Money Valeant Pharmaceuticals’ (VRX) new CEO Joseph Papa may have spoken too soon in his pledge to begin to curb drug prices that had been hiked to controversial levels — especially as the drugmaker’s roughly $31 billion debt package did...
by qfrsolutions | Jul 25, 2016 | News
Source: CNBC Journey Medical Corporation, a subsidiary of Fortress Biotech, Inc. (FBIO), launched the first two prescription products in its dermatology franchise, Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion. Both products will be showcased...
by qfrsolutions | Jul 13, 2016 | News
Source: The Wall Street Journal Michael Pearson has sold nearly $100 million of his stock in Valeant Pharmaceuticals International Inc. in the past two weeks, according to securities filings, following his firing as the troubled drugmaker’s chief executive in...
by qfrsolutions | Jul 8, 2016 | News
Source: Galderma, a global leader focused on medical solutions in skin health, today announced that its U.S. affiliate, Galderma Laboratories, L.P. received approval from the U.S. Food and Drug Administration (FDA) for Differin® Gel (adapalene gel 0.1%) as an...
